首页> 美国卫生研究院文献>Stem Cells Translational Medicine >Functional Effects of a Tissue-Engineered Cardiac Patch From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Rat Infarct Model
【2h】

Functional Effects of a Tissue-Engineered Cardiac Patch From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Rat Infarct Model

机译:组织工程性心脏修补程序从人类诱导的多能干细胞衍生的心肌细胞在大鼠梗死模型中的功能作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A tissue-engineered cardiac patch provides a method to deliver cardiomyoctes to the injured myocardium with high cell retention and large, controlled infarct coverage, enhancing the ability of cells to limit remodeling after infarction. The patch environment can also yield increased survival. In the present study, we sought to assess the efficacy of a cardiac patch made from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to engraft and limit left ventricular (LV) remodeling acutely after infarction. Cardiac patches were created from hiPSC-CMs and human pericytes (PCs) entrapped in a fibrin gel and implanted acutely onto athymic rat hearts. hiPSC-CMs not only remained viable after in vivo culture, but also increased in number by as much as twofold, consistent with colocalization of human nuclear antigen, cardiac troponin T, and Ki-67 staining. CM+PC patches led to reduced infarct sizes compared with myocardial infarction-only controls at week 4, and CM+PC patch recipient hearts exhibited greater fractional shortening over all groups at both 1 and 4 weeks after transplantation. However, a decline occurred in fractional shortening for all groups over 4 weeks, and LV thinning was not mitigated. CM+PC patches became vascularized in vivo, and microvessels were more abundant in the host myocardium border zone, suggesting a paracrine mechanism for the improved cardiac function. PCs in a PC-only control patch did not survive 4 weeks in vivo. Our results indicate that cardiac patches containing hiPSC-CMs engraft onto acute infarcts, and the hiPSC-CMs survive, proliferate, and contribute to a reduction in infarct size and improvements in cardiac function.
机译:组织工程化的心脏贴片提供了一种将心肌梗塞传递至受损心肌的方法,该方法具有高的细胞滞留率和可控的大梗塞覆盖率,增强了细胞限制梗塞后重塑的能力。补丁环境还可以提高生存率。在本研究中,我们试图评估由人诱导的多能干细胞衍生的心肌细胞(hiPSC-CMs)制成的心脏贴片在梗塞后急性植入并限制左心室(LV)重塑的功效。由hiPSC-CM和包裹在纤维蛋白凝胶中的人周细胞(PC)创建心脏贴片,然后将其急性植入无胸腺大鼠心脏。 hiPSC-CMs在体内培养后不仅保持活力,而且数量增加了两倍,这与人核抗原,心肌肌钙蛋白T和Ki-67染色的共定位一致。与仅使用心肌梗塞的对照组相比,CM + PC贴片导致梗塞面积减小,并且在移植后1和4周,CM + PC贴片的接受者心脏在所有组中的分数缩短幅度都更大。但是,所有组的缩短分数均在4周内下降,并且LV变薄并未得到缓解。 CM + PC贴片已在体内形成血管,并且宿主心肌边界区域的微血管更为丰富,这提示了旁分泌机制可改善心脏功能。仅PC对照贴片中的PC在体内无法存活4周。我们的结果表明,含有hiPSC-CM的心脏斑块会移植到急性梗塞中,并且hiPSC-CM能够存活,增殖并有助于减少梗塞面积并改善心脏功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号